Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant
- PMID: 35458384
- PMCID: PMC9031584
- DOI: 10.3390/v14040654
Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant
Abstract
Rapid antigen detection (RAD) tests are commonly used for the diagnosis of SARS-CoV-2 infections. However, with the continuous emergence of new variants of concern (VOC), presenting various mutations potentially affecting the nucleocapsid protein, the analytical performances of these assays should be frequently reevaluated. One hundred and twenty samples were selected and tested with both RT-qPCR and six commercial RAD tests that are commonly sold in Belgian pharmacies. Of these, direct whole-genome sequencing identified the strains present in 116 samples, of which 70 were Delta and 46 were Omicron (BA.1 and BA.1.1 sub-lineages, respectively). The sensitivity across a wide range of Ct values (13.5 to 35.7; median = 21.3) ranged from 70.0% to 92.9% for Delta strains and from 69.6% to 78.3% for Omicron strains. When taking swabs with a low viral load (Ct > 25, corresponding to <4.9 log10 copies/mL), only the Roche RAD test showed acceptable performances for the Delta strains (80.0%), while poor performances were observed for the other RAD tests (20.0% to 40.0%). All the tested devices had poor performances for the Omicron samples with a low viral load (0.0% to 23.1%). The poor performances observed with low viral loads, particularly for the Omicron strain, is an important limitation of RAD tests, which is not sufficiently highlighted in the instructions for use of these devices.
Keywords: Delta; Omicron; RT-qPCR; SARS-CoV-2; antigen; variant.
Conflict of interest statement
Among the authors, J.D. (Jonathan Douxfils) is CEO and founder of QUALIblood s.a., a contract research organization manufacturing the DP-Filter, is co-inventor of the DP-Filter (patent application number: PCT/ET2019/052903) and reports personal fees from Daiichi-Sankyo, DOA-Sense, Gedeon Richter, Mithra Pharmaceuticals, Portola, Stago, Roche and Roche Diagnostics outside the submitted work. The other authors have no conflict of interest to disclose.
Figures
References
-
- Caruana G., Croxatto A., Kampouri E., Kritikos A., Opota O., Foerster M., Brouillet R., Senn L., Lienhard R., Egli A. ImplemeNting SARS-CoV-2 Rapid antigen testing in the Emergency wArd of a Swiss univErsity hospital: The INCREASE study. Microorganisms. 2021;9:798. doi: 10.3390/microorganisms9040798. - DOI - PMC - PubMed
-
- EU Health Preparedness: A Common List of COVID-19 Rapid Antigen Tests; A Common Standardised Set of Data to Be Included in COVID-19 Test Result Certificates; and a Common List of COVID-19 Laboratory based Antigenic Assays. [(accessed on 16 February 2022)]. Available online: https://ec.europa.eu/health/sites/default/files/preparedness_response/do....
-
- Favresse J., Gillot C., Oliveira M., Cadrobbi J., Elsen M., Eucher C., Laffineur K., Rosseels C., Van Eeckhoudt S., Nicolas J.-B. Head-to-head comparison of rapid and automated antigen detection tests for the diagnosis of SARS-CoV-2 infection. J. Clin. Med. 2021;10:265. doi: 10.3390/jcm10020265. - DOI - PMC - PubMed
-
- Salcedo N., Nandu N., Boucau J., Herrera B.B. Detection of SARS-CoV-2 Omicron, Delta, Alpha and Gamma variants using a rapid antigen test. medRxiv. 2022:1–17. doi: 10.1101/2022.01.27.22269299v1. - DOI
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
